Autologous peripheral blood mononuclear cell surface proteins (Autologous PBMC surface proteins)

Autologous peripheral blood mononuclear cell (PBMC) surface proteins represent the collective set of membrane-bound molecules found on a patient's own immune cells, including lymphocytes and monocytes (National Cancer Institute, 2024). These proteins are not a single molecular target but serve as a broad substrate for specialized immunotherapies and extracorporeal treatments. In therapies such as extracorporeal photopheresis (ECP), these surface proteins are modified using agents like methoxsalen and ultraviolet light to induce immunomodulatory effects, which are used to treat cutaneous T-cell lymphoma and graft-versus-host disease (StatPearls, 2023). Furthermore, autologous PBMCs are utilized in the production of cellular vaccines, such as Sipuleucel-T, where the cells are activated ex vivo to target specific cancer antigens (FDA, 2010). The interaction with these proteins often aims to reprogram the immune system or eliminate malignant cell populations through selective apoptosis. Because this target encompasses a vast array of distinct receptors and antigens, it is considered a procedural or cellular target rather than a specific biochemical entity (Journal of Clinical Apheresis, 2020).

Other names

Autologous PBMC antigensAutologous mononuclear cell surface markersPatient-derived PBMC surface proteinsAutologous peripheral blood mononuclear cells

Ex vivo modification of cell surface proteins to induce immunomodulation, selective apoptosis of pathogenic T-cell clones, or activation of antigen-presenting cells (StatPearls, 2023; FDA, 2010).